Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 144 for “"PROTAC"”.
-
Investigating a PROTAC approach to NRF2 activation
… More recently, proteolysis-targeting chimeras (PROTACs) have emerged as a novel strategy to activate NRF2 by degrading Keap1, offering enhanced potency, selectivity and duration of action compared to PPI inhibitors and small molecules. In this project, TAT-14 was synthesised by Fmoc solid-phase …
-
Machine Learning for PROTAC Decomposition and Enhanced Degradation Prediction
PROTACs (Proteolysis Targeting Chimeras) are bifunctional molecules composed of three components that mediate the degradation of target proteins, and are widely used in drug discovery. This project explores the application of machine learning in two key aspects: splitting PROTAC molecules into …
-
Discovery of DYR684, a First-in-Class DYRK1A/B PROTAC
… of DYRK1 proteolysis targeting chimeras (PROTACs) that combine a new ATP-competitive DYRK1 inhibitor with ligands for the E3 ubiquitin ligase component Cereblon (CRBN) to induce ubiquitination and subsequent proteasomal degradation of DYRK1A and DYRK1B. The lead compound (DYR684) promoted …
-
Exploring linker fluorination to optimise PROTAC potency, selectivity, and physical properties
PROteolysis TArgeting Chimeras (PROTACs) have emerged as an exciting new modality in drug discovery for catalytically inducing targeted protein degradation. They consist of protein binding ligands for an E3 ubiquitin ligase and the protein to be degraded joined together by a linker, the length and …
-
Understanding the structure-activity relationship (SAR) and PK of PROTAC linkers
Proteolysis targeting chimeras (PROTACs) are a relatively new class of heterobifunctional molecules that have been identified as a potential anti-cancer therapy. They work by bringing a protein of interest (POI) and E3 ligase proteins in proximity and triggering ubiquitination and subsequent …
-
Development of a Peptide-based PROTAC Incorporating a β-hairpin Sequence
… the proteasome. Proteolysis targeting chimeras (PROTACs) have emerged as a novel therapeutic agent to selectively degrade ‘undruggable’ targets; however, many peptide-based PROTACs suffer low cell permeability and high protease susceptibility. The goal of this work is to utilize degron-based …
-
The discovery of first RET PROTAC with <em>in vivo</em> activity
… development of RET Proteolysis targeting chimera PROTAC molecules based on Selpercatinib (LOXO-292) and Sulfono-γ-AApeptide PROTAC. A PROTAC molecule is a bifunctional molecule composed of two active domains and a linker. It works by inducing selective protein intracellular degradation. This …
-
Effect of stabilising mutations in β-catenin on PROTAC-mediated degradation kinetics
Protein degrader drugs such as PROTACs have emerged as a chemical strategy to degrade pathological proteins via recruitment to E3 ubiquitin ligase complexes. How the basal rate of target protein turnover influences PROTAC-mediated degradation is incompletely understood. To address this question, I …
-
PROTAC-mediated degradation of phospholamban as a novel therapeutic strategy for heart failure
Abstract not currently available.
-
Design, synthesis and evaluation of mechanism-based inhibitors of IDO1 and PROTAC-degraders of JAK2
… family members. Proteolysis targeting chimeras (PROTACs) have the ability to degrade proteins within cells by harnessing the ubiquitin-proteasomal system. Based on FDA-approved JAK2 ligand fedratinib, a series of PROTACs were synthesised. The synthesised PROTACs were evaluated in JAK2-expressing …
-
Developing Computational Methods in Proximity Pharmacology for Enzyme Discovery, PROTAC Screening, and Conformational Space Exploration
… called Proteolysis Targeting Chimeras (PROTACs), have shown clinical promise, with two currently in Phase 3 trials. Beyond degradation, the field of proximity pharmacology explores the recruitment of other enzymes, such as kinases, to induce post-translational modifications. While …
-
Design, Synthesis and Characterisation of Novel Linker Chains under Conformational Control for PROTAC Drug Discovery
… for the conformational study of small-molecule, PROTAC linker and peptidomimetic foldamer, with applications for rational structure-based drug design.
-
SUBUNIT PEPTIDE-ENCAPSULATING NANOPARTICLE HIV VACCINE TARGETING CYTOTOXIC T LYMPHOCYTE ACTIVATION VIA PROTAC-ENHANCED CROSS PRESENTATION
… Inspired by proteolysis-targeting chimera (PROTAC) technologies which have been employed for in situ destruction of cancer-related proteins, this project explores the incorporation of a proteolysis targeting moiety (ProTM) in vaccination. We hypothesize that by conjugating an E3 ubiquitin …
-
Investaging the role of KIFC1 and centrosome amplification in metastatic uveal melanoma : Towards building a protac to target KIFC1
… molecule inhibitors is the use of small-molecule PROTACs, which are bifunctional chimeras that hijack the ubiquitin-proteasome system to induce degradation of disease-causing target proteins, while also working at lower concentrations and with better specificity than the small molecule inhibitors …
-
Development and application of BromoTag : A “Bump-&-Hole”- PROTAC degron system for rapid, potent, and selective degradation of tagged target proteins
… via new bumped proteolysis targeting chimaeras (PROTACs) to induce the degradation of the genetically engineered protein target. We developed an endogenous BromoTag platform that we used in the extensive optimisation of BromoTag bump-and-hole-PROTACs. Our cellular data collectively qualify PROTAC …
-
Machine Learning for Structural Predictions of PROTACs
PROteolysis TArgeting Chimeras (PROTACs) are molecules that induce the degradation of targeted proteins by hijacking the ubiquitin–proteasome system in the cell. A PROTAC binds simultaneously to an E3 ligase and a protein of interest (POI), forming a ternary complex. The ubiquitin–proteasome system …
Page 1 of 8